- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Octillion Corp. today announced the appointment of nanostructured photovoltaic and sustainable materials expert Dr. Jeffrey R. S. Brownson of the Penn State University to the Company's Advisory Board.
Octillion Corp. (OTCBB: OCTL), a next-generation alternative and renewable energy technology incubator, today announced the appointment of nanostructured photovoltaic and sustainable materials expert Dr. Jeffrey R. S. Brownson of the Penn State University to the Company's Advisory Board.
Enhancing the Company's ongoing development of a spectrally selective, nanosilicon-enabled inorganic photovoltaic for use in glass windows and skylights, Dr. Brownson brings highly relevant industry experience with the Cardinal Coated Glass Company, exceptional proficiency in the synthesis, characterization, and deposition of photovoltaic and photocatalytic nanomaterials, and unparalleled access to equipment and resources through the National Nanotechnology Infrastructure Network (www.nnin.org), the Materials Research Institute (www.gonano.psu.edu), and the Penn State Institutes of Energy and the Environment (http://www.environment.psu.edu).
"Dr. Brownson brings an unusually complementary set of values, skills, and experiences to the Octillion team," stated Mr. Nicholas S. Cucinelli, President and CEO of Octillion Corp. "His views on sustainability and ‘environmental premeditation' in materials synthesis are entirely consistent with our efforts to use one of the most abundant materials in the Earth's crust—silicon—to produce a truly transparent photovoltaic window with a high net-energy ratio, excellent optical properties, and sound economics."
Dr. Brownson's widely published research and leadership efforts include the innovative science blog Nanomech in Photovoltaics (http://nanoparis.blogspot.com), which is dedicated to the "interdisciplinary exploration of third generation photovoltaics, environmental technology, and scientific philosophy." He is the faculty director for the 2009 Penn State Solar Decathlon team, Natural Fusion (www.solar.psu.edu) and author of several highly relevant papers such as "FTIR Study of Methanol and Ethanol Interactions with Anatase Surfaces with Respect to UV Irradiation" (Journal of Physical Chemistry B, 2006) and "Electrophoretic Deposition of Template-Free ZnO Nanorod Films" (ECS Transactions 2007).
"It has been a great pleasure to get to know Mr. Cucinelli and learn about Octillion's substantial efforts toward creating a transparent nanostructured solar device," stated Dr. Brownson. "I'm honored to join the exceptional team Mr. Cucinelli is assembling; critical thinkers with diversified backgrounds who can add context to the significant energy challenges at hand."
Dr. Brownson continued, "Octillion resonates with me and the bright young minds I work with for pursuing basic materials research within a context of building integrated photovoltaic (BIPV) design. The PV window concept is exciting from an energy and architectural standpoint, and there is ample work to be done in developing a figure of merit that accurately quantifies the value of the viewscape, daylighting, energy production, and solar heat gain control attributes of such a product. Furthermore, Mr. Cucinelli's vision for a truly novel, sustainability-oriented business model is exactly suited to the mind set of the current generation of researchers and students."
Before joining the faculty at The Pennsylvania State University in 2007, Dr. Brownson completed two Post-Doctoral programs: one with Cardinal Glass CG (Spring Green, WI), where he developed photocatalytic thin films on glass, synthesized nanostructured metal oxides for inorganic solar cell devices, and assembled and characterized quantum dot solar cell devices; and a second at the Institut de Chimie et Matériaux de Paris-Est, CNRS (Centre National de la Recherche Scientifique), Thiais, France where he synthesized metal chalcogenide and metal oxide/hydroxide thin films on transparent conductive electrodes, electrodeposited light-absorbing nanoparticles over mesoporous TiO2 thin films for inorganic-sensitized photovoltaic cells, and synthesized inorganic fullerines by ultrasonic spray thermolysis.
Mr. Cucinelli continued, "I expect Dr. Brownson's prior experience with Cardinal Glass and CNRS, his access to the Penn State Materials Research Institute and broader resources of the NNIN, and his hands-on work with the 2009 PSU Solar Decathlon team to significantly enhance and further inspire our ongoing research. Dr. Brownson's collaborative and interdisciplinary approach to scientific research and problem solving is a perfect fit within the growing Octillion team."
Dr. Brownson holds a PhD in Environmental Chemistry and Technology and an M.S. degree in Geology, both from the University of Wisconsin, Madison, where he specialized in the synthesis and characterization of metal oxide nanoparticles for high surface area applications, ultrasonic spray delivery for thin-film deposition, and surface characterization using High Resolution Transmission Electron Microscopy (HRTEM). He also holds a B.S. in Geology (Magna cum laude) from the University of North Dakota.
About Octillion Corp.
Octillion Corp. is a technology incubator focused on the identification, acquisition, development and eventual commercialization of emerging solar energy and solar related technologies.
Among our current research and development activities is the development of a technology that could adapt existing home and office glass windows into ones capable of generating electricity from solar energy without losing significant transparency or requiring major changes in manufacturing infrastructure.
For additional information, please visit: http://www.octillioncorp.com
To receive future press releases via email, please visit:
http://www.octillioncorp.com/OCTL_20071128.html of this release
Legal Notice Regarding Forward-Looking Statements
No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although Octillion Corp. (the “Company” or “Octillion”) believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company's products, technical problems with the Company's research and products, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company's operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company's ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our on going research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and /or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Octillion will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company's most recent Form 10-QSB and Form 10-KSB filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission at http://www.sec.gov . The Company undertakes no obligation to publicly release the results of any revisions to these forward looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
For more information, please click here
Mr. Nicholas S. Cucinelli
Suite 2 - 2638 Lapeer Road
Auburn Hills, MI 48326
Copyright © Octillion Corp.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
New nano approach could cut dose of leading HIV treatment in half February 24th, 2017
New nano approach could cut dose of leading HIV treatment in half February 24th, 2017
NREL research pinpoints promise of polycrystalline perovskites February 8th, 2017